Factors associated with depressive state in patients with myasthenia gravis: A multicentre cross-sectional study

BMJ Open

Volumn 1, Issue 2, 2011, Pages

  Suzuki, Yasushi ^a   Utsugisawa, Kimiaki ^b   Suzuki, Shigeaki ^c   Nagane, Yuriko ^b   Masuda, Masayuki ^d   Kabasawa, Chiaki ^e   Shimizu, Yuko ^e   Utsumi, Hiroya ^d   Uchiyama, Shinichiro ^e   Fujihara, Kazuo ^f   Suzuki, Norihiro ^c  

^a SENDAI CITY MEDICAL CENTER   (Japan)

^b Hanamaki General Hospital   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855512395     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000313     Document Type: Article

References (20)

1. Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci 1999;170:77-89. (Pubitemid 29528529)
2. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007;21:473-81. (Pubitemid 46849183)
3. Köhler W. Psychosocial aspects in patients with myasthenia gravis. J Neurol 2007;254(Suppl 2):II/90-2. (Pubitemid 46763921)
4. Paradis CM, Friedman S, Lazar RM, et al. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry 1993;150:1102-4. (Pubitemid 23198632)
5. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.
6. Steer RA, Clark DA, Beck AT, et al. Common and specific dimensions of self-reported anxiety and depression: the BDI-II versus the BDI-IA. Behav Res Ther 1999;37:183-90.
7. Fisher J, Parkinson K, Kothari MJ. Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromuscul Dis 2003;4:105-8. (Pubitemid 38404416)
8. Kojima M, Furukawa TA, Takahashi H, et al. Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res 2002;110:291-9. (Pubitemid 34804537)
9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendation for clinical research standards. Neurology 2000;55:16-23.
10. Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-9. (Pubitemid 29190546)
11. Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74:1434-40.
12. Suzuki S, Utsugisawa K, Nagane Y, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 2007;64:1121-4. (Pubitemid 47258071)
13. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375-91.
14. Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396-402. (Pubitemid 26422526)
15. Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harv Rev Psychiatry 1998;5:239-46. (Pubitemid 28092100)
16. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-90.
17. Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988;77:443-5.
18. Doering S, Henze T, Schüssler G. Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 1993;50:617-20. (Pubitemid 23165592)
19. Paul RH, Nash JM, Cohen RA, et al. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001;24: 512-16. (Pubitemid 32246787)
20. Paul RH, Cohen RA, Goldstein JM, et al. Severity of mood, selfevaluative, and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000;12:499-501.